Dick H Burkhard, Schultz Tim, Gerste Ronald D
University Eye Clinic, Ruhr University, Bochum, Germany.
Ophthalmol Ther. 2019 Mar;8(1):19-30. doi: 10.1007/s40123-019-0161-2. Epub 2019 Feb 6.
In the management of glaucoma, recent and upcoming innovations have the potential to contribute to both the efficacy of intraocular pressure (IOP) monitoring and the number of available treatment options. These new devices and procedures have two things in common: they are part of the trend in medicine towards miniaturization, and they require a limited surgical procedure to become effective. This review focuses on the Eyemate (Argos) intraocular sensor, which offers a new way to reliably measure 24 h IOP, and on intraocular sustained release systems for pharmacological glaucoma therapy. It also briefly reflects on the miniature implants currently used in minimally invasive glaucoma surgery (MIGS).
在青光眼的管理方面，近期及即将出现的创新技术有可能提高眼内压（IOP）监测的效果，并增加可用的治疗选择数量。这些新设备和程序有两个共同点：它们是医学向小型化发展趋势的一部分，并且它们需要有限的外科手术来发挥作用。本综述重点关注Eyemate（Argos）眼内传感器，它提供了一种可靠测量24小时眼内压的新方法，以及用于青光眼药物治疗的眼内缓释系统。它还简要介绍了目前用于微创青光眼手术（MIGS）的微型植入物。
